Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda study shows benefits of new dengue vaccine

Takeda study shows benefits of new dengue vaccine

8th November 2017

Takeda has announced the findings of a new clinical study that highlights the promise shown by TAK-003, its new dengue vaccine candidate.

Results from the ongoing phase II DEN-204 trial have been published in The Lancet Infectious Diseases, showing how the live, attenuated tetravalent dengue vaccine candidate performed well over an 18-month period.

TAK-003 was shown to be associated with a reduction in the incidence of dengue in children and adolescents aged from two to 17 living in dengue-endemic areas, including the Dominican Republic, Panama and the Philippines.

The vaccine induced sustained antibody responses against all four serotypes of dengue virus, regardless of previous dengue exposure and dosing schedule. It is hoped that forthcoming data from the phase III TIDES efficacy trial can confirm these benefits.

Derek Wallace, global dengue programme lead at Takeda, said: "We are seeing an acceptable safety profile and sustained antibody responses out to 18 months in this trial. This data is an important step in the development of our dengue vaccine candidate."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.